Logo

NKTX

Nkarta, Inc.

NKTX

Nkarta, Inc. • NASDAQ
$1.89 ▲ 3.01% (+0.06)
Market Cap $133.89 M
52w High $3.15
52w Low $1.31
Dividend Yield 0%
P/E -1.37
Volume 524.61K
Outstanding Shares 71.03M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $27.286M ▲ $-21.715M ▲ 0% $-0.29 ▲ $-19.409M ▲
Q2-2025 $0 $27.186M ▼ $-22.977M ▲ 0% $-0.31 ▲ $-24.855M ▲
Q1-2025 $0 $36.564M ▲ $-31.983M ▼ 0% $-0.43 ▼ $-29.165M ▼
Q4-2024 $0 $30.923M ▼ $-25.935M ▲ 0% $-0.35 ▲ $-28.635M ▲
Q3-2024 $0 $33.794M $-28.344M 0% $-0.39 $-31.447M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $282.331M ▼ $427.236M ▼ $89.336M ▼ $337.9M ▼
Q2-2025 $289.687M ▲ $448.312M ▼ $90.644M ▼ $357.668M ▼
Q1-2025 $265.507M ▼ $470.609M ▼ $91.804M ▼ $378.805M ▼
Q4-2024 $267.354M ▼ $501.203M ▼ $93.227M ▼ $407.976M ▼
Q3-2024 $283.055M $532.034M $101.161M $430.873M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-21.715M ▲ $-18.687M ▲ $25.387M ▲ $0 ▼ $6.7M ▲ $-18.679M ▲
Q2-2025 $-22.977M ▲ $-18.753M ▲ $19.492M ▼ $77K ▲ $816K ▼ $-18.891M ▲
Q1-2025 $-31.983M ▼ $-29.612M ▼ $54.337M ▲ $0 ▼ $24.725M ▲ $-30.13M ▼
Q4-2024 $-25.935M ▲ $-24.751M ▼ $-4.52M ▲ $184K ▲ $-29.087M ▲ $-25.854M ▼
Q3-2024 $-28.344M $-24.545M $-38.895M $2K $-63.438M $-25.322M

Five-Year Company Overview

Income Statement

Income Statement Nkarta is still a pure research-stage biotech, with essentially no product revenue so far. Its income statement is dominated by R&D and related operating expenses, which lead to steady annual losses. Those losses have grown as the company has advanced its pipeline, though there are signs of modest improvement in per‑share loss recently. The overall picture is typical for a young clinical‑stage biotech: spending heavily to develop its platform long before any commercial payback.

Balance Sheet

Balance Sheet The balance sheet shows a company funded mainly by equity rather than debt, which limits financial leverage risk but depends on continued investor support. Total assets have grown over time, reflecting capital raised and investment into the platform and clinical programs. Cash is meaningful but not dominant within total assets, suggesting a mix of cash, short‑term investments, and other R&D assets. Debt remains relatively small compared with equity, which is positive for flexibility but does not remove the long‑term need for fresh capital if trials continue for many years.

Cash Flow

Cash Flow Nkarta consistently uses cash rather than generates it, as expected for a company without revenue and with ongoing clinical trials. Operating cash outflows have risen over time, mirroring higher R&D and development activity. Capital spending is modest, so most of the cash burn is tied to people, trials, and manufacturing capabilities rather than big physical assets. The company’s path forward will likely rely on periodic external financing, partnerships, or other funding sources until it can reach a commercial stage.

Competitive Edge

Competitive Edge Nkarta operates in a crowded and fast‑moving cell therapy field but is carving out a specialty in off‑the‑shelf natural killer cell therapies for autoimmune disease. Its approach aims to combine better safety, easier logistics, and lower cost than personalized cell therapies, which could be compelling if the data hold up. Focusing on B‑cell–driven autoimmune conditions gives it a potentially large and underserved market, yet it also puts Nkarta head‑to‑head with other advanced therapies targeting similar biology. The company’s competitive standing will ultimately depend on how its safety, efficacy, and ease of use compare to rivals such as CAR‑T players and other CAR‑NK developers.

Innovation and R&D

Innovation and R&D Innovation is the core of Nkarta’s value: its platform uses engineered NK cells with built‑in support signals designed to last longer and work more effectively in the body. The off‑the‑shelf manufacturing model and cryopreservation capabilities are key differentiators, allowing many treatment doses from a single donor and potentially smoother scaling. Lead candidate NKX019 targets B‑cells and is being tested across multiple autoimmune indications, reflecting a broad strategy to show the platform’s versatility. Early data suggest encouraging safety and immune‑reset potential, but these are still early‑stage trials, and much of the scientific and clinical promise remains to be proven in larger, longer studies.

Summary

Nkarta is a classic high‑risk, high‑uncertainty, early‑stage biotech story built around a differentiated cell therapy platform. Financially, it has no revenue, ongoing losses, and steady cash burn, supported mainly by equity with modest use of debt. Strategically, it is pursuing a large opportunity in autoimmune disease with technology that could offer safety and manufacturing advantages over existing cell therapies. The main value drivers ahead are clinical trial readouts, continued validation of safety and durability, and the company’s ability to secure enough funding and partnerships to carry its programs through later‑stage development. Until then, its outlook is highly dependent on scientific outcomes and capital market conditions.

NEWS

November 10, 2025 · 4:01 PM UTC

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

Read more

October 30, 2025 · 1:14 PM UTC

Nkarta to Participate in November Investor Conferences

Read more

October 22, 2025 · 10:07 AM UTC

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

Read more

September 2, 2025 · 8:01 AM UTC

Nkarta to Participate in a September Investor Conference

Read more